Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | FADS1 | O60427 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595547 | 0.95 | CDK4 (0.49) | CDK4CDK2TNFFADS1MEN1 | |
| SCHEMBL3377743 | 0.76 | TNF (0.55) | CDK4CDK2TNFFADS1MEN1 | |
| SCHEMBL24773786 | 0.75 | BACE1 (0.36) | CDK4CDK2MEN1KMT2ABACE1 | |
| SCHEMBL4738586 | 0.75 | FADS1 (0.58) | TNFFADS1MEN1KMT2ANPC1 | |
| SCHEMBL3377751 | 0.74 | GRM4 (0.59) | TNFFADS1MEN1KMT2ACCNB2 | |
| SCHEMBL4787755 | 0.73 | FADS1 (0.55) | TNFFADS1MEN1KMT2ANPC1 | |
| SCHEMBL3955863 | 0.72 | NPC1 (0.66) | TNFFADS1MEN1KMT2ACCNB2 | |
| SCHEMBL4787756 | 0.70 | FADS1 (0.52) | TNFFADS1MEN1KMT2ANPC1 | |
| SCHEMBL4933191 | 0.70 | TNF (0.64) | TNFFADS1MEN1KMT2AHTR3E | |
| SCHEMBL6159474 | 0.69 | CDK2 (1.00) | CDK4CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659401-B2 | N-(2-methyl-7-pyridin-3-yl-thiazolo[4,5-c]pyridin-4-yl)-N-(2(4)-methyl-thiazol-4(2)-yl)-amine; metabotropic glutamate receptor antagonists; mGluR5 receptor mediated disorders; nervous system disorders; analgesics; incontinence; liver disorders; obesity; Fragile x syndrome; autism;Alzeimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2010-02-09 | — | — | US | claimed |
| EP-1948667-A2 | THIAZOLO[4,5-C]PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | claimed |
| WO-2007054436-A2 | THIAZOLO [4 , 5-C] PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-20070105891-A1 | Thiazole[4,5-C]pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-05-10 | — | — | US | claimed |
| US-7659401-B2 | N-(2-methyl-7-pyridin-3-yl-thiazolo[4,5-c]pyridin-4-yl)-N-(2(4)-methyl-thiazol-4(2)-yl)-amine; metabotropic glutamate receptor antagonists; mGluR5 receptor mediated disorders; nervous system disorders; analgesics; incontinence; liver disorders; obesity; Fragile x syndrome; autism;Alzeimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1948667-A2 | THIAZOLO[4,5-C]PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054436-A2 | THIAZOLO [4 , 5-C] PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105891-A1 | Thiazole[4,5-C]pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105891-A1 | Thiazole[4,5-C]pyridine derivatives | GRM5, GRIK5, GRM1 | CDK4 1046/4885CDK2 1183/4885TNF 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.